<p>Bacillus Calmette-Guerin (BCG) administration plays a central role in managing carcinoma in situ of the bladder. Unfortunately, recurrence or progression of disease is seen in up to 30% of treated patients. Disclosed herein is a method for predicting responsiveness to treatment with BCG based on BCG internalization by bladder cancer cells, the presence or absence of mutations associated with BCG uptake or a combination thereof.</p>
申请公布号
AU2013299643(A1)
申请公布日期
2015.03.26
申请号
AU20130299643
申请日期
2013.08.07
申请人
MEMORIAL SLOAN-KETTERING CANCER CENTER
发明人
GLICKMAN, MICHAEL;JIANG, XUEJUN;BARKAN, DANIEL;REDELMAN-SIDI, GIL;IYER, GOPA;SOLIT, DAVID;BOCHNER, BERNARD H.